Uterine side effects of tamoxifen: A need for systematic pretreatment screening

Obstetrics and Gynecology

Volumn 91, Issue 1, 1998, Pages 40-44

  Berlière, Martine ^a   Charles, Alain ^a   Galant, Christine ^a   Donnez, Jacques ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER RISK; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HIGH RISK POPULATION; HUMAN; HYSTEROSCOPY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; SCREENING; UTERUS DISEASE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA IN SITU; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDIES; TAMOXIFEN; TIME FACTORS;

EID: 0031982689     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00591-7     Document Type: Article

References (22)

1. 1. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645-51.
2. 2. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WN. Endometrial cancer in tamoxifen treated breast cancer patients; findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B 14. J Natl Cancer Inst 1994;86:527-37.
3. 3. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;1:117-20.
4. 4. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640-9.
5. 5. Friedl A, Jordan VC. What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat 1994;1:27-39.
6. 6. Jordan VC. Molecular mechanisms of antioestrogen action in breast cancer. Breast Cancer Res Treat 1994;31:41-52.
7. 7. Nephen KP, Polek TC, Khan SA. Tamoxifen-induced protooncogene expression persists in uterine endometrial epithelium. Endocrinology 1996;137:219-24.
8. 8. Carmichael PL, Ugwumadu AH, Neven P, Hewer AJ, Poon GK, Phillips DH. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996;56:1475-9.
9. 9. Powles TJ, Jones AL, Ashley SE, O'Brien MER, Tidy VA, Treleovan J, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trials. Breast Cancer Res Treat 1994;3:73-82.
10. 10. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy. 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 1992;339:1-15, 71-85.
11. 11. Cohen I, Rosen D, Tepper R, Cordoba M, Shapira Y, Altaras M, et al. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993;5:275-80.
12. 12. Kurman RJ, Norris HJ. Endometrial hyperplasia and related cellular changes. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. 4th ed. New York: Springer Verlag, 1994:411-37.
13. 13. Kurman RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. 4th ed. New York: Springer Verlag, 1994:439-86.
14. 14. Cohen I, Altaras MM, Beyth Y, Weed JC. Gynecologic tumors in tamoxifen treated women with breast cancer. Obstet Gynecol 1994;81:158-9.
15. 15. Cohen I, Rosen DJD, Shapiro J, Cordoba M, Gilboa S, Altaras MM, et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567-70.
16. 16. Neven P, De Muylder X, Van Belle Y, Campo R, Vanderick G. Tamoxifen and the uterus: Women given this drug need careful assessment. BMJ 1994;309:1313-4.
17. 17. Nuovo MA, Muovo GJ, Mc Caffey RM, Leviner V, Barron B, Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125-31.
18. 18. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990;35:235-8.
19. 19. Gal D, Kopel S, Basheukin M, Lebowicz J, Lev R, Tancer L. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer. Preliminary report. Gynecol Oncol 1991;42:120-3.
20. 20. Sasco AJ, Raffi F, Satge D, Goburdhun J, Fallou HB, Leduc B. Endometrial müllerian carcinosarcoma after cessation of tamoxifen therapy for breast cancer. Int J Gynaecol Obstet 1995;48:307-10.
21. 21. Magriples U, Naftolin F, Schartz PC, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
22. 22. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32:1464-76.